Free Trial

Zevra Therapeutics (ZVRA) Short Interest Ratio & Short Volume

Zevra Therapeutics logo
$7.43 -0.23 (-3.00%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$7.43 0.00 (0.00%)
As of 04/3/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zevra Therapeutics Short Interest Data

Zevra Therapeutics (ZVRA) has a short interest of 5.57 million shares, representing 10.40% of the float (the number of shares available for trading by the public). This marks a -0.71% decrease in short interest from the previous month. The short interest ratio (days to cover) is 12.0, indicating that it would take 12.0 days of the average trading volume of 589,687 shares to cover all short positions.

Current Short Interest
5,570,000 shares
Previous Short Interest
5,610,000 shares
Change Vs. Previous Month
-0.71%
Dollar Volume Sold Short
$46.29 million
Short Interest Ratio
12.0 Days to Cover
Last Record Date
March 15, 2025
Outstanding Shares
54,116,000 shares
Float Size
53,550,000 shares
Short Percent of Float
10.40%
Today's Trading Volume
450,725 shares
Average Trading Volume
589,687 shares
Today's Volume Vs. Average
76%
Short Selling Zevra Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Zevra Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ZVRA Short Interest Over Time

ZVRA Days to Cover Over Time

ZVRA Percentage of Float Shorted Over Time

Remove Ads

Zevra Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/15/20255,570,000 shares $46.29 million -0.7%10.4%12 $8.31
2/28/20255,610,000 shares $44.94 million -2.9%10.6%13.1 $8.01
2/15/20255,780,000 shares $46.64 million +4.7%10.9%13.4 $8.07
1/31/20255,520,000 shares $43.28 million +0.9%10.5%10.7 $7.84
1/15/20255,470,000 shares $43.81 million +17.1%10.3%10.3 $8.01
12/31/20244,670,000 shares $38.95 million +14.7%8.8%7.7 $8.34
12/15/20244,070,000 shares $34.51 million -5.6%7.7%5.5 $8.48
11/30/20244,310,000 shares $40.21 million +4.9%8.1%5.1 $9.33
11/15/20244,110,000 shares $35.43 million +4.3%7.7%4.8 $8.62
10/31/20243,940,000 shares $32.11 million -21.2%7.5%4.6 $8.15
10/15/20245,000,000 shares $41.90 million +5.5%9.6%4.5 $8.38
9/30/20244,740,000 shares $32.90 million +25.7%9.1%4.3 $6.94
9/15/20243,770,000 shares $29.59 million -1.6%7.2%3.9 $7.85
8/31/20243,830,000 shares $29.30 million +0.3%7.3%5 $7.65
8/15/20243,820,000 shares $27.24 million -13.2%7.3%5.4 $7.13
7/31/20244,400,000 shares $28.56 million +38.8%10.6%7.2 $6.49
7/15/20243,170,000 shares $19.75 million +7.1%7.6%11.2 $6.23
6/30/20242,960,000 shares $14.50 million +7.3%7.1%12.1 $4.90
6/15/20242,760,000 shares $12.83 million +7.4%6.6%13.2 $4.65
5/31/20242,570,000 shares $11.95 million -4.1%6.2%11.8 $4.65
5/15/20242,680,000 shares $12.92 million +1.1%6.5%11.6 $4.82
4/30/20242,650,000 shares $12.14 million +11.8%6.2%10.6 $4.58
4/15/20242,370,000 shares $11.34 million +5.3%5.9%9.6 $4.79
3/31/20242,250,000 shares $13.05 million +5.6%5.6%9.1 $5.80
3/15/20242,130,000 shares $12.78 million -0.9%5.6%7.7 $6.00
2/29/20242,150,000 shares $14.49 million +0.9%5.6%7.8 $6.74
2/15/20242,130,000 shares $14.23 million No Change5.6%8.1 $6.68
1/31/20242,130,000 shares $12.33 million +1.0%5.6%8.3 $5.79
1/15/20242,110,000 shares $12.49 million +1.4%5.5%8.8 $5.92
12/31/20232,080,000 shares $13.62 million +13.7%5.5%9 $6.55
12/15/20231,830,000 shares $8.72 million -9.4%4.8%10.2 $4.77
11/30/20232,020,000 shares $9.62 million -15.1%5.4%12.6 $4.76
11/15/20232,380,000 shares $10.07 million +4.4%6.3%14.8 $4.23
10/31/20232,280,000 shares $10.21 million No Change7.0%16.3 $4.48
10/15/20232,280,000 shares $10.19 million -3.0%7.0%16.7 $4.47
9/30/20232,350,000 shares $11.33 million -10.0%7.7%16.8 $4.82
9/15/20232,610,000 shares $13.39 million +6.1%8.5%17 $5.13
8/31/20232,460,000 shares $12.47 million -3.9%8.0%10.4 $5.07
8/15/20232,560,000 shares $13.39 million +3.6%8.4%10.4 $5.23
7/31/20232,470,000 shares $12.05 million -4.3%8.1%9.1 $4.88
Trump’s betrayal exposed (Ad)

Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.

Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma
7/15/20232,580,000 shares $12.26 million +0.8%8.4%8.7 $4.75
6/30/20232,560,000 shares $13.06 million +20.8%8.4%8.4 $5.10
6/15/20232,120,000 shares $12.49 million +3.9%6.9%6.8 $5.89
5/31/20232,040,000 shares $10.28 million +4.1%6.7%8.3 $5.04
5/15/20231,960,000 shares $8.55 million No Change6.4%7.7 $4.36

ZVRA Short Interest - Frequently Asked Questions

What is Zevra Therapeutics' current short interest?

Short interest is the volume of Zevra Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 5,570,000 shares of ZVRA short. 10.40% of Zevra Therapeutics' shares are currently sold short. Learn More on Zevra Therapeutics' current short interest.

What is a good short interest ratio for Zevra Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZVRA shares currently have a short interest ratio of 12.0. Learn More on Zevra Therapeutics's short interest ratio.

Which institutional investors are shorting Zevra Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Zevra Therapeutics: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Zevra Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.40% of Zevra Therapeutics' floating shares are currently sold short.

Is Zevra Therapeutics' short interest increasing or decreasing?

Zevra Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 5,570,000 shares, a decrease of 0.7% from the previous total of 5,610,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Zevra Therapeutics' float size?

Zevra Therapeutics currently has issued a total of 54,116,000 shares. Some of Zevra Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Zevra Therapeutics currently has a public float of 53,550,000 shares.

How does Zevra Therapeutics' short interest compare to its competitors?

10.40% of Zevra Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Zevra Therapeutics: Vera Therapeutics, Inc. (14.81%), Galapagos NV (4.19%), Kiniksa Pharmaceuticals, Ltd. (9.36%), Mesoblast Limited (2.57%), IDEAYA Biosciences, Inc. (12.22%), Immunocore Holdings plc (17.17%), ANI Pharmaceuticals, Inc. (14.05%), Schrödinger, Inc. (13.35%), Amphastar Pharmaceuticals, Inc. (10.94%), Wave Life Sciences Ltd. (7.71%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

What does it mean to sell short Zevra Therapeutics stock?

Short selling ZVRA is an investing strategy that aims to generate trading profit from Zevra Therapeutics as its price is falling. ZVRA shares are trading down $0.23 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Zevra Therapeutics?

A short squeeze for Zevra Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ZVRA, which in turn drives the price of the stock up even further.

How often is Zevra Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZVRA, twice per month. The most recent reporting period available is March, 15 2025.




This page (NASDAQ:ZVRA) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners